Role of curcumin in regulating p53 in breast cancer: an overview of the mechanism of action

Wamidh H Talib1
Sonia A Al-hadid1
Mai B Wild Ali1
Intisar Hadi AL-Yasari2
Mohammed R Abd Ali3
1Department of Clinical Pharmacy and Therapeutics, Applied Science Private University, Amman, Jordan; 2Food Technology Department, Faculty of Food Science, AL-Qasim Green University, Babylon, Iraq; 3Faculty of Nursing, University of Babylon, Babylon, Iraq

Abstract: p53 is a tumor suppressor gene involved in various cellular mechanisms including DNA repair, apoptosis, and cell cycle arrest. More than 50% of human cancers have a mutated nonfunctional p53. Breast cancer (BC) is one of the main causes of cancer-related deaths among females. p53 mutations in BC are associated with low survival rates and more resistance to the conventional therapies. Thus, targeting p53 activity was suggested as an important strategy in cancer therapy. During the past decades, cancer research was focused on the development of monotargeted anticancer therapies. However, the development of drug resistance by modulation of genes, proteins, and pathways was the main hindrance to the success of such therapies. Curcumin is a natural product, extracted from the roots of Curcuma longa, and possesses various biological effects including anticancer activity. Previous studies proved the ability of curcumin to modulate several signaling pathways and biomolecules in cancer. Safety and cost-effectiveness are additional inevitable advantages of curcumin. This review summarizes the effects of curcumin as a regulator of p53 in BC and the key molecular mechanisms of this regulation.

Keywords: natural products, apoptosis, p53, breast cancer, Curcuma longa

Introduction

Cancer is one of the most common causes of death globally. In the late 20th century, researchers predicted about 1.3 million new invasive cancer cases in USA and 560,000 deaths which means 1,500 Americans died from cancer per day.1 Unfortunately, this number increased and reached around 1.6 million new cases and 589,430 deaths in 2015 with almost 1,600 deaths per day.2 By 2030, WHO International expected that 25% of people around the world will have at least one cancer type. More than 60% of new cases are expected in low- and middle-income regions.3

An interesting study showed that approximately 14.1 million people in USA had a history of cancer in all sites.4 A preliminary study estimated that 3,131,440 women live in USA diagnosed with invasive breast cancer (BC). In 2014 alone, 232,670 women had invasive BC and almost 72% of them were older than 60 years.4 Recent statistics showed a marked increase in new BC cases, and there were 231,840 cases in 2015 while clinicians estimated 246,660 new cases in the followed year.5 In 2017, new BC in situ cases were the highest among females at the age of 50–59 years.6

The use of natural products in cancer therapy is an active area of research, and previous studies reported the successful use of some plant extracts and pure compounds to treat different cancers.7 Curcumin is one of the extensively studied natural products. It has numerous health benefits and many pharmacological effects including...
antiproliferation, apoptosis induction, antiangiogenesis, anti-inflammatory, and antioxidant activities. Its low cost and ability to attack multiple targets in cancer make it a suitable agent to be explored for cancer management.9

p53 is a tumor suppressor gene involved in many metabolic processes including apoptosis induction, repairing DNA damage, and inducing arrest in cell cycle. More than 50% of human tumors lost the protective effect of p53 which results in resistance to apoptosis and sustained proliferation.10 Selective inhibition of cancer cells requires specific disruption of growth mechanisms used by these cells with limited damage to normal cells. In this context, p53 is considered as one of the suitable targets as more than half of the human cancers have mutated p53.11

In this review, the effects of curcumin in apoptosis induction and p53 activity regulation are discussed.

Side effects of conventional anticancer therapies

Chemotherapy has been and remains one of the first available options for BC patients with early or late stages.12 Unfortunately, chemotherapeutics cause a number of serious, unpleasant, may be fatal, side effects. In addition, these drugs fail to evade multidrug resistance phenomenon which limited their efficacy.13 Many years ago, cardiac toxicity was a well-known side effect of both anthracyclines and mitoxantrone which cause arrhythmias and congestive heart failure (CHF) with cumulative doses of more than 160 mg/mL due to oxidative stress, while antimetabolites such as fluorouracil cause CHF due to vasospasm.14

Cancer patients who undergo chemotherapy treatment in concomitant with other antiemetic drugs and opioids will develop severe painful constipation and remarked downstream effect on colonic motility and gastrointestinal (GI) transit.15 Furthermore, the platinum-based chemotherapeutic agent, oxaliplatin, induces apoptosis in crypts within the colon and causes excessive secretions, and thus some patients develop diarrhea.16,17 Cisplatin, an alkylating antitumor agent, causes heart block and ischemia,18 as well as it causes severe nephrotoxicity due to the enormous renal proximal tubular cell death which will increase serum creatinine levels after a few days of administration.19 Additional side effects noticed by researchers were ototoxicity, hepatotoxicity, and declining of white and red blood cells among cisplatin users.19 At the very least, the short-term use of chemotherapy causes ephemeral immunosuppression and thus induces serious parasitic, viral, and fungal infections.20

Radiotherapy (RT) is another standard anticancer therapy.21 However, its use is associated with many side effects.22 Patients who are sensitive to radiation were expected to develop subcutaneous and lung fibrosis.21 In addition, the local treatment of a squamous cell carcinoma of head and neck by RT will certainly develop skin toxicities such as erythema and desquamation.24 Furthermore, BC women who received RT experienced emotional discomfort and pain. One patient did not repeat the therapy after feeling an extensive burning in the breast.25

Moreover, late symptoms may emerge due to the use of RT, such as proctitis, diarrhea, and cystitis during 2 years of follow-up using a radical RT in prostate cancer patients.26,27 A case study reported another late symptom which is the second malignancy; four out of 14,000 patients who had been treated for their childhood Wilms tumor using a radiation therapy developed hepatocellular carcinoma as a second malignant neoplasm (SMN) and death occurs on average of 3 months after diagnosis.28,29 These side effects encouraged scientists to search for alternative therapeutic options that exhibit low toxicity and high ability to selectively target cancer cells. Plant-derived natural products are an ideal source of such therapies due to their diversity and capacity to target multiple growth pathways in cancer.

Curcumin in cancer research

For years now, the world has been turning to use herbal remedies and natural products to extract effective biological constituents against cancer. This trend is due to serious side effects of the conventional treatments.7,30,31 WHO reported that 80% of world inhabitants depend on plant-derived traditional medicine in health care.32 In 2050, the global market of pharmaceutical preparations derived from plants will grow and reach $5.0 trillion.33 The most important herbal trademarket (China) exports 120,000 tones of herbal drugs per year.34 There are more than 250,000 plant species in our globe, and only 10% were tested for certain biological evidence.35,36 However, half of the currently marketed drugs are of plant origin.37

Many plant-derived natural products have anticancer potential.38 From 1981 to 2010, 30 years of effort showed that around 80% of the anticancer drugs isolated directly from natural products or mimicked them, while only 20% were synthesized in the laboratories.39 One of the most struggling issues in cancer therapy is multidrug resistance phenomenon which arises in 30–80% of patients who undergo chemotherapy.40 Fortunately, most of
the natural products have been able to resist this phenomenon such as curcumin while most of the synthetic agents failed to deal with it.40

As reported by Shishodia et al, curcumin was isolated by Vogel in 1842 and the chemical structure was identified by Lamp in 1910.41 It was derived from the roots of Curcuma longa and has multiple health benefits including antioxidant, anti-inflammatory, chemopreventive, and chemotherapeutic effect.42

Curcuma longa or turmeric is cultivated widely in India and contains 60–70% of curcumin ([1E,6E]-1,7-bis[4-hydroxy-3-methoxyphenyl]-1,6-heptadiene-3,5-dione; Figure 1).31,45 Researchers found that curcumin has many biological activities due to the huge chemical diversity of its metabolites.44

The most important metabolites are vanillin and ferulic acid, which have cytotoxic effects represented by overahul mutated oxygenase-2 enzyme (COX-2) and NF-kB.43

Curcumin is an ancient herb and has modulated numerous molecular targets in cancer research. It downregulated receptors (Her-2, IR, ER-a, and Fas receptor), growth factors (PDGF, TGF, FGF, and EGF), kinases (JAK, PAK, and mitogen-activated protein kinase [MAPK]), enzymes (ATPase, COX-2, and matrix metalloproteinase enzyme [MMP]), inflammatory cytokines (IL-1, IL-2, IL-6, IL-8, IL-12, and IL-18), and transcriptional factors (nuclear factor kappa B protein [NF-κB], Notch-1, and STAT-1, STAT-3, STAT-4, and STAT-5), while it upregulated other targets including p53, death receptor (DR-5), JN-kinase, Nrf-2, and peroxisome proliferator-activated receptor γ (PPARγ) factors.46

Curcumin targets many cancer hallmarks. First, it has an antitumorigenic effect through decreasing the expression of MMP-2 and increasing the expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), where both enzymes regulate cell invasion.48 Second, it has an antiproliferative effect by inhibiting the transcription of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF).49 In addition, curcumin has a potential to bind to aminopeptidase N (CD13) and thus inhibits VEGF receptor, decreases the expression of MMP-9, and withstands tyrosine kinase signaling pathway.49 Also, it decreases the expression of cyclin-dependent protein kinase-2 (CDK-2) in colon cancer.50

An interesting study on prostate cancer cell lines, PC3 and DU145, inferred that curcumin has a dose-dependent effect on both cell viability and proliferation. Researchers concluded that curcumin depresses the survival of previously mentioned cell lines at a concentration of 50 µM. A time-dependent inhibition of curcumin on the same cell lines decreased survival by 50% in 48 hours.51

Recently, cancer stem cells showed an essential role in progressing many types of cancers. Curcumin can defeat cancer through targeting these cells such as Burkitt lymphoma, acute myeloid leukemia, liver, and colorectal cancer.52,53 In specific, the activity of BC stem cells (BCSCs) was inhibited by curcumin after Western blot analysis of BCSC markers (CD44, ALDH1A1, Nanog, and Oct4) that were substantially downregulated by curcumin also in MCF-7 cells. On the other hand, curcumin induced apoptosis of BCSCs by reducing BCL-2 protein levels and increasing many apoptotic proteins such as Bcl-2-associated X protein (Bax), caspase-3, caspase-8, and caspase-9.54

Mainly, there are factors affecting curcumin efficacy such as low hydrophilicity, low bioavailability, and rapid metabolism; thus, it delivered in several formulations that enhanced the solubility, efficacy, and cytotoxicity of this phytochemical.55 Curcumin has been used in about 26 clinical trials of several diseases starting from psychotic disorders, Alzheimer disease, cognitive ailment, and ending with many types of cancer.56 As a lipophilic compound, it showed frustrating clinical studies when given orally; thus, it formulated in various drug delivery systems such as nanoparticle, liposome, microemulsion, and implantable devices. Nanoparticle-formulated curcumin gained several advantages, increased oral bioavailability by 26-fold, and lengthened half-life and retention time in gastric acids which enhanced its efficacy.57 An interesting study on MCF-7 cells compared between the anticancer effects of free curcumin and curcumin loaded on a nanocarrier used increasing concentrations of both delivery formulas (0.5–70 µM) and resulted in boosting the cytotoxicity of curcumin and time of the release and reducing IC50.58

Role of p53 in cancer progression

Human p53 gene can encode 12 different isoforms that normally formed through an alternative initiation of translation and alternative splicing.10 The p53 protein composed of 393
amino acids which grouped into six domains. First is the N-terminal region which consists of the transcription activation domain (TAD) and is subdivided into two regions (TD1 and TD2). Second is the proline-rich region (PRR), which is constant in a majority of p53s. Third is the central core domain (p53C), where the DNA-binding part is located and more than 90% of human mutations take place. Fourth is a nuclear localization signal domain. Fifth is a tetramerization (TET) domain. Sixth is the C-terminal domain (CT), which is the nonspecific DNA-binding domain. 

p53 is considered a target for many posttranslational modifications, such as phosphorylation, acetylation, and ubiquitination. Several signals can generate p53 within minutes, including ultraviolet (UV) radiation, hypoxia, blockage of transcription, oncogene signaling, ionizing radiation, and lack of nucleotides. Then, p53 will induce cell cycle arrest, and apoptosis and block angiogenesis and DNA repair (Figure 2).

Any mutation occurs in p53 may lead to an oncogenic action. Most human cancers have a mutated p53 gene which leads to a total or partial loss of its function. This mutant p53 is associated with cancer due to loss of function (LoF) and dominant negative (DN) and gain-of-function (GoF) effects.

Only about 5% of p53 mutations found in the regulatory domains, whereas 95% found in the central region which is responsible for a sequence-specific DNA binding. Frequently, mutations take place in this region of p53 (residues 102–292). Unlike other tumor suppressor genes, more than 85% of p53 mutations caused by a single amino acid substitution.

The central role of p53 in cell survival makes it a target for many therapeutic anticancer strategies. Restoring endogenous p53 expression resulted in tumor regression of animal models, and response varies depending on tumor type. For example, p53 restoration induces apoptosis in lymphoma, while it causes suppression of cell growth and senescence in sarcoma; these successful results support the research for treating cancer by pharmacological reactivation of p53. In BC, p53 suppression increases a gene expression that encodes Burkitt lymphoma receptor BLR-1 which binds to chemokine ligand 13 (CXCL13) and thus activates both cell migration and metastasis.

p53 protein plays a substantial role in activating adaptive cellular responses to environmental stresses. There are many routes to activate p53 protein such as posttranslational modification, protein stabilization, and protein–protein interaction. After all, the main route is the p53-murine double minute 2 (MDM2) pathway which destabilizes p53.

p53 is a short-lived tumor suppressor protein, and its levels are controlled by MDM2 protein. The regulation process involves binding of the MDM2 protein to the transactivation domain of p53 which is followed by ubiquitination and rapid turnover of p53.

Wild-type p53 increases the expression of MDM2, and the first intron of MDM2 binds to p53 on a DNA-binding region near the promoter which will induce gene expression. When additional levels of MDM2 are produced, p53’s activity will decrease, which is a mechanism called autoregulatory feedback loop.

---

**Figure 2**: p53 stimulation signals and downstream effects. Abbreviation: UV, ultraviolet.
Mutated MDM2 can negatively regulate p53 levels by degrading the phosphorylated form of this protein, and it can be amplified in 30–40% of human sarcomas which indicates the MDM2 critical role in developing this type of cancer.70

Any loss in the p53 function will contribute to cancer development due to the major role of this protein in preventing tumor growth at several points of the malignancy process.71,72 The function of p53 lost in many different ways; the most common one is a loss of the chromosomal region that contains one allele of the gene and mutations in the other allele.70

**Role of p53 in apoptosis**

Apoptosis can be induced by p53 through the activation of caspase–cascade pathway in both transcription-dependent or transcription-independent mechanisms.73,74 Transcription-independent mechanism occurs when p53 induces the transcription of a gene encoding protein such as the Fas protein which is essential to promote apoptosis.73,75 On the other hand, the transcription-dependent mechanism occurs when p53 boosts the expression of pro-apoptotic proteins such as Bax which is the key of the intrinsic pathway of apoptosis.74,75

Therapeutic strategies of targeting p53 focused on increasing p53 levels to induce apoptosis, inhibiting the interaction between p53 and MDM2 and restoring wild-type p53.76 The genetic mutation that activates oncogenes can inhibit many tumor suppressor genes and lead to cancer development. Tumor-associated p53 mutations inhibit the activity of p53 and trigger an alteration in the activity of pro-apoptotic proteins.77,78

Deficiency in p53 levels plays a role in cancer drug resistance; a clinical study showed that tumor cells with a mutant-type p53 were resistant to chemotherapy and radiotherapy.79 Additional clinical studies are associated with poor clinical outcomes in cancer therapy due to an inhibition of functional p53 family proteins such as p73 and p63. Furthermore, a mutant-type p53 can upregulate the expression of some genes involving multidrug resistance-1 (MDR1) gene, which is the contributor to the drug resistance phenomenon.76

A positive correlation was observed between p53 function and the degree of response to certain cancer therapies. For instance, tumors with mutated p53 such as lung cancer and prostate cancer exhibited poor response to chemotherapy. In addition, p53 mutations positively correlated with doxorubicin resistance in BC patients.80

The role of curcumin in regulating p53 in BC

In healthy human adults, 150 billion \(10^9\) cells out of 37.2 trillion \(10^{12}\) cells will undergo apoptosis on daily basis.81 Curcumin has an anti-proliferative effect and acts as a pro-apoptotic agent in many cancer cell lines.82 It can induce apoptosis by p53 activation and regulation of other apoptotic proteins.83 Specifically, p53 is activated by curcumin after it is translocated into the nucleus of a cancer cell.84 In addition, curcumin upregulates the expression of apoptotic genes such as TRAP3 and MCL-1 and downregulates other genes such as TRAIL and AP13 in BC cells.85

The exposure of human BC cell lines (MCF-7) to curcumin induces p53 DNA-binding activity and increases p53 to its maximum level; this is associated with the increased levels of an apoptotic activator known as Bax.86,87 Further studies reported additional upregulated genes by curcumin in this cell line which included many genes induced by the tumor suppressor protein (p53) and which are involved in p53-mediated programmed cell death.88,89

Drastically, curcumin induces Bax and p21 expression which results in apoptosis and cell cycle arrest, respectively.82 p21 is one of the downstream genes that are being transactivated by p53.90 In fact, curcumin activates p53 directly which repairs DNA and it also inactivates serine/threonine-specific protein kinase (Akt) which resulted in increased expression of Bax gene and induction of apoptosis.91,92

In another human BC cell line (MDA-MB-231), curcumin induces apoptosis in a dose-dependent manner through increasing the levels of both Bax and p21 proteins while reducing an antiapoptotic protein B cell lymphoma-2 (Bcl-2) levels along with decreasing p53 levels. The latter effect does not confirm many other studies which have reported that curcumin induces apoptosis by p53-dependent Bax in human BC cell line (MCF-7).93-95

Curcumin regulates many molecular targets which involved in the intrinsic apoptotic pathway of BC cells, and it upregulates the serine phosphorylation of p53 and inhibits the phosphorylation of Akt which modulates the direct action of p53 on the caspase–cascade network.96,97 It downregulates mutant p53 and activates caspase-3, the hallmarks of apoptosis, which will prevent cancer progression.98

Cancer cells that express high levels of mutant p53 are more sensitive to curcumin treatment than those that express a wild-type p53; curcumin selectively increases the levels of wild-type p53 at a G2/M phase in deregulated cyclin D1-overexpressing cells.99 When using high doses of curcumin, not only it exerts an effect on G2/M phase but also it induces S phase with no observed pre-G1 peak.100

In addition, curcumin may induce apoptosis through activating p53 and downregulating PI3K, p-Akt, and p-mTOR substrates; PI3k/Akt/mTOR is a well-known survival pathway
activated by cancer cells progressively. In another mechanism, curcumin activates PPARY which transactivates p53, the major mediator of cell senescence. Curcumin alone can induce the expression of p53 gene (Trp53) and thus restore the level as well as the function of the p53 protein.

In multiple myeloma cancer cells treated with curcumin, the expression of p53 and Bax genes is upregulated, while the expression of the MDM2 gene is downregulated. Curcumin causes overexpression and reactivation of p53. In the same fashion, it is able to restore the active wild-type p53 form in various cancer cell origins and activates p53 cousin, a p73 protein, which induces apoptosis depending on the mitochondria-mediated pathway.

**Figure 3** The role of curcumin in regulating p53 in BC.

**Abbreviation:** BC, breast cancer.

**Table 1** The effects of curcumin on p53 in vitro: a sample of studies

<table>
<thead>
<tr>
<th>Cell lines</th>
<th>Tumor inoculation</th>
<th>Curcumin (dose, route)</th>
<th>Response</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDA-MB-231, epithelial cells of mammary gland; breast, metastatic mammary adenocarcinoma</td>
<td>LL-15 medium; l-glutamine, 10% FBS and Abs</td>
<td>5 µg/mL, for 48 hours</td>
<td>⇩ 50–60% inhibition of proliferation ⇩ Cyclin D1 expression ⇩ levels of p21</td>
<td>126</td>
</tr>
<tr>
<td>BT-483, epithelial cells of mammary gland; breast, ductal carcinoma</td>
<td>Dulbecco’s Modified Eagle (DME) medium; l-glutamine, 10% FBS and Abs</td>
<td>5 µg/mL, for 48 hours</td>
<td>⇩ 60–70% inhibition of proliferation ⇩ CDK-4 expression</td>
<td>127</td>
</tr>
<tr>
<td>T-47D, epithelial cells of mammary gland; breast, DCIS</td>
<td>RPMI-1640 media; l-glutamine, nonessential amino acids, 10% FBS, and Abs</td>
<td>5–80 µM CUR, for 24 hours</td>
<td>⇩ 20–80 µM of CUR significantly decreases p53 protein levels</td>
<td>128</td>
</tr>
<tr>
<td>EAC, mammary epithelial carcinoma cells</td>
<td>DME or RPMI-1640 medium</td>
<td>10 µM of CUR, for 2 hours</td>
<td>⇩ p65NF-xB, NF-xB ⇩ p53-p300, Bax, Noxa PUMA ⇩ Intrinsic cascade of death ⇩ p21, p27 ⇩ Cyclin-D1, cyclin-E, cyclin-A, CDK-2, and CDK-4</td>
<td>129</td>
</tr>
<tr>
<td>MCF-7, epithelial cells of mammary gland; breast, adenocarcinoma</td>
<td>RPMI-1640 medium</td>
<td>48 hours</td>
<td>⇩ p53 levels, Bax ⇩ Bcl-xl/Bax ratio ⇩ Bcl-2 ⇩ Phospho-p53, PPARγ</td>
<td>91</td>
</tr>
<tr>
<td>MCF-7, epithelial cells of mammary gland; breast, adenocarcinoma</td>
<td>DME medium</td>
<td>10 µM of CUR, for 24 hours</td>
<td>⇩ Induce apoptosis ⇩ p53 levels, Bax ⇩ Bcl-xl/Bax ratio ⇩ Bcl-2 ⇩ Phospho-p53, PPARγ</td>
<td>130</td>
</tr>
<tr>
<td>SK-BR-3 cells, malignant adenocarcinoma of the breast</td>
<td>McCoy’s 5A medium</td>
<td>30 µM of CUR, for 24 hours</td>
<td>⇩ PTEN, p-AKT, p-MDM2, p53 ⇩ Protective effect against bisphenol A, through modulation of miR-19/PTEN/AKT/p53 axis</td>
<td>131</td>
</tr>
<tr>
<td>MCF-7, epithelial cells of mammary gland; breast, adenocarcinoma</td>
<td>DME medium</td>
<td>1 µM of CUR, for 4 days</td>
<td>⇩ Phospho-p53, PPARγ</td>
<td>132</td>
</tr>
<tr>
<td>MDA-MB-231, metastatic mammary adenocarcinoma</td>
<td>DME medium</td>
<td>40 µM of CUR, for 72 hours</td>
<td>⇩ The number of cells in the early stages of apoptosis, total p53 levels, phospho-Bad (ser112)</td>
<td>132</td>
</tr>
<tr>
<td>MCF-7, epithelial cells of mammary gland; breast, adenocarcinoma</td>
<td>DME medium</td>
<td>40 µM of CUR, for 72 hours</td>
<td>⇩ The number of cells in the early stages of apoptosis, total p53 levels, phospho-Bad (ser112)</td>
<td>132</td>
</tr>
</tbody>
</table>

**Note:** Abs, antibiotics such as penicillin, streptomycin, and amphotericin B; BT-483, ER-positive BC cell line; MDA-MB-231, ER-negative BC cell line; SK-BR-3, Her-2-positive, ER-negative, PR-negative; T-47D, human BC cell line, positive for both ER and PR. 

**Abbreviations:** Akt, protein kinase B; BC, breast cancer; Bcl-2, B cell lymphoma-2; CDK, cyclin-dependent kinase; CUR, curcumin; DCIS, ductal carcinoma in situ; EAC cells, Ehrlich ascites carcinoma, doxorubicin-resistant cells; ER, estrogen receptor; LL-15 medium, Leibovitz’s L-15 medium; PR, progesterone receptor; PTEN, phosphatase and tensin.
Generally speaking, curcumin is effective in treating cancer cells that contain an abnormal p53 and experience resistance to conventional therapies due to an abnormality in p53 expression or function. Researchers found that curcumin can cause apoptosis independently on p53 status by increasing superoxide anion production and phosphorylation of oxidative stress proteins.\(^{109}\) In addition, it arrests cancer cells in G1/G0 phase and thus inhibits proliferation in a p53-independent pathway.\(^{110}\) Moreover, It induces cell cycle arrest at G2 phase in p53-deficient BC cells.\(^{111}\)

Curcumin exerts a cytotoxic effect through inducing necrotic cell death relying on Bax, caspase-dependent activation, and cytochrome C release from mitochondria.\(^{112}\) It increases cancer cell apoptosis through an overexpression of p53 and modulation of Bax and Bcl-2 molecules in a dose-dependent manner.\(^{113,114}\) By the same token, it induces cytotoxic effect due to cancer cell stress sensed by p53, cytoplasmic activation of this protein, and nuclear translocation resulted in restoring the transcriptional function of p53 protein.\(^{115}\)

Curcumin induces p53 phosphorylation on serine 15 moiety which increases accumulation of this protein in cancer cells.\(^{116}\) This phytochemical also induces ROS production which leads to an increase in the levels of p53 and in its downstream proteins such as p21 and Bax.\(^{117}\)

Curcumin can induce apoptosis in a p53-independent manner, especially in cancer cells that lack a functional p53 protein by downregulating pro-survival protein (Bcl-2) and p38 MAPK.\(^{118,119}\) This dietary natural compound inhibits the p300-mediated acylation of p53 that interacts with the p300/CBP complex to enhance its transcriptional effect.\(^{120}\) Additionally, other molecular targets for curcumin were reported in several studies testing its anticancer effect against breast cancer.\(^{121-125}\) Figure 3 summarizes the main regulatory points of curcumin in BC. In addition, in vitro studies on various BC cell lines in addition to a brief summary about the inhibitory effects of curcumin in animal models are listed in Tables 1 and 2, respectively.

### Table 2 The effect of curcumin on animal models bearing malignant breast tumors in vivo: a sample of studies

<table>
<thead>
<tr>
<th>Animal models</th>
<th>Tumor inoculation</th>
<th>Curcumin (dose, route)</th>
<th>Response</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female Foxn1nu/nu mice, 6–8 weeks old</td>
<td>s.c. injection of mba.mbb231 cells into the right side flank, 2.5×10^6</td>
<td>Diet containing curcumin at 0.6%</td>
<td>Proliferation of mba.mbb231 cells, Apoptosis and p53 expression, Expression of CD-1, PECAM-1 and p65</td>
<td>133</td>
</tr>
<tr>
<td>Swiss albino mice, 23–25 g</td>
<td>i.p. injection of EAC cells, 1×10⁴</td>
<td>CUR 50 mg/kg body weight</td>
<td>p65NF-κB, NF-κB, p53-p300, Bax, Noxa PUMA, Intrinsic cascade of death</td>
<td>128</td>
</tr>
<tr>
<td>Female nu/nu athymic mice, 7 weeks</td>
<td>i.p. of 1.7 mg of 17β-estradiol before inoculation, MCF-7 cells 1×10⁴/mL</td>
<td>100 mg/kg of CUR, for 28 days</td>
<td>p21, p27, Cyclin-D1, cyclin-E, cyclin-A, CDK-2, and CDK-4, Cell cycle arrest</td>
<td>129</td>
</tr>
<tr>
<td>Female athymic nude mice, orthotopic model</td>
<td>Injection of 2×10⁶ of MDA-MB-435LB cells</td>
<td>Fed with powdered diet containing 2% w/w curcumin</td>
<td>NF-κB, COX-2, and MMP-9</td>
<td>134</td>
</tr>
<tr>
<td>Female BALB/c nude mice, 35–40 days old, 20–22 g, xenograft tumor</td>
<td>s.c. with 2×10⁶ MDA-MB-231 cells into the dorsa of each mouse</td>
<td>i.p., 50 µg/kg and 200 µg/kg every other day for 28 days</td>
<td>Apoptosis in a dose-dependent manner, Bax protein levels, Bcl-2 protein levels</td>
<td>135</td>
</tr>
<tr>
<td>Female BALB/c mice weighing about 18–23 g</td>
<td>i.p. of EAT cells, 1×10⁴/animal</td>
<td>i.p. injection, 9.9 µg/mL daily, 10 days</td>
<td>Apoptosis, apoptotic bodies, phosphorylated caspase-3</td>
<td>136</td>
</tr>
<tr>
<td>nu/nu mice, xenografts</td>
<td>s.c. of BT-474, in the flank</td>
<td>8.7 mM/kg of body weight/day, dietary supplementation</td>
<td>Release of cytochrome c by mitochondria, chemotherapy-induced apoptosis, ROS formation, JNK activation</td>
<td>137</td>
</tr>
<tr>
<td>Female BALB/c, 8-week-old mice</td>
<td>100 µL of 4T1 cell suspension</td>
<td>2,000 µg/kg body weight of CUR-encapsulated microspheres, for 30 days</td>
<td>Downregulate p-AKT, Apoptosis, upregulate p27, upregulate cleaved caspase-3</td>
<td>138</td>
</tr>
</tbody>
</table>

**Note:** MDA.MB231, ER-negative BC cell line; MDA-MB-435LB cells, human BC cells; Noxa, promotes activation of caspases and apoptosis; 4T1, triple-negative BC cells; nu/nu, nude mice.

**Abbreviations:** BC, breast cancer; Bcl-2, B cell lymphoma-2; COX-2, cyclooxygenase; CUR, curcumin; EAT, Ehrlich ascitic tumor cells; murine mammary adenocarcinoma; i.p., intraperitoneal; JNK, c-Jun NH2-terminal kinase; MMP-9, matrix metalloproteinases 9; NF-κB, nuclear factor kappa B protein; PECAM-1, platelet and endothelial cell adhesion molecule-1; PUMA, p53 upregulated modulator of apoptosis; s.c., subcutaneously; EAC cells, Ehrlich ascites carcinoma, doxorubicin-resistant cells.
Conclusion
The numerous health benefits of curcumin, its cost-effectiveness, and its ability to target multiple components in BC make it an ideal agent for further development to produce more effective therapies against BC. This compound interferes with BC proliferation by upregulating pro-apoptotic proteins (such as p53 and Bax) and downregulating antiapoptotic proteins (such as MDM2 and Bcl-2). Many animal and clinical studies supported the use of curcumin to treat different cancer types including BC. Curcumin can be considered for further testing to augment conventionalanticancer therapies. However, the low bioavailability of this phytochemical is one of the main problems to be solved before using it as a standard therapeutic agent to treat cancer.

Disclosure
The authors report no conflicts of interest in this work.

References


